Osteoarthritis affects around 600 million people globally. It causes pain, stiffness and reduced joint function – most commonly in the knees, hands and hips. There’s currently no cure for ...

Knee osteoarthritis is a complex disease that affects the whole joint, including bone, cartilage, ligaments and muscles. Osteoarthritis is a common cause of pain and movement difficulty, affecting 8.3 ...

While GLP-1 weight loss meds have been a mainstay in pop culture for a few years now, they're potentially about to get even more widespread. Formerly only available as an injection, Wegovy recently ...

Colorado regulators have approved a dramatic price cap on one of the nation’s best-selling drugs, cutting its price to less than one-third of its previous level, in a novel attempt by a state to ...

Real-world data suggest anti-TNF biosimilars for juvenile idiopathic arthritis offer comparable efficacy and safety to their brand name counterparts. As high-cost originator biologics continue to ...

Original Medicare covers most medically necessary treatments for rheumatoid arthritis (RA), including biologics like adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Inflectra), and ...

Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on ...

Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the United States. And unless a court rules otherwise, the Southern California ...

(RTTNews) - Sandoz (SDZNY) has initiated an antitrust lawsuit in the United States against Amgen, Inc. (AMGN), accusing the company of maintaining its dominant market position for the blockbuster drug ...

Medicare was authorized to negotiate prices it will pay for Part D drugs. Enbrel, the original version of etanercept, was among the first 10 drugs to be subject to negotiations. The negotiated price ...